Pošalji tekstualnu poruku: PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES